Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intranasal Human Abuse Liability (HAL) study to compare the opioid abuse potential after a single dose of hydrocodone extended-release tablet (crushed) versus intranasal hydrocodone powder

Next Previous
Trial Profile

Intranasal Human Abuse Liability (HAL) study to compare the opioid abuse potential after a single dose of hydrocodone extended-release tablet (crushed) versus intranasal hydrocodone powder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocodone (Primary) ; Hydrocodone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Teva Pharmaceutical Industries

    • Most Recent Events

    • 25 Feb 2015 According to a Teva Pharmaceutical Industries media release, the US FDA has accepted for review an NDA supported in part by results of this study and another study investigating the abuse potential of CEP 33237.
    • 07 Nov 2014 New trial record
    • 08 Oct 2014 Data from this study will support the NDA submission to the US FDA which is expected to be completed by the end of 2014, according to a Teva Pharmaceutical Industries media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top